Amboy Street Ventures Invests in Juniper Genomics’ $4.6M Seed Round to Advance a New Standard in IVF Embryo Screening
Amboy Street Ventures is pleased to announce its participation in the $4.6 million seed round for Juniper Genomics, a company transforming care in IVF with the world’s first embryo screening test powered by whole-genome and transcriptome sequencing. The round was led by Company Ventures, with participation from Amboy Street Ventures, Innospark Ventures, MBX Capital, Dria Ventures, and Blue Collective.
Infertility affects 1 in 6 people, and IVF is often the chosen path—but with a 34% success rate per cycle, many endure multiple costly, emotionally taxing rounds. A leading cause of failed embryo transfers in IVF is genetic abnormalities, many of which go undetected by traditional screening methods.
Juniper Genomics is addressing this critical gap. Juniper’s single test replaces almost all existing forms of preimplantation genetic testing by leveraging analysis of thousands of clinically relevant genetic variants linked to IVF failure, miscarriage, and life-threatening medical conditions after birth. The result is the clearest, most detailed, and actionable view of embryo health and viability available today.
Unlike other embryo testing startups, Juniper does not rely on polygenic or genetic risk scores. Instead, Juniper screens for specific genetic changes known to cause adverse pregnancy outcomes and serious health conditions. Juniper’s analytical depth, coupled with integrated genetic counseling, offers both physicians and patients actionable data to make more informed decisions, reducing the physical, emotional, and financial burden associated with repeated IVF cycles.
“Juniper Genomics is bringing an unprecedented level of clarity, accuracy, and compassion to one of the most personal and difficult decisions prospective parents face,” said Carli Sapir, Founding Partner at Amboy Street Ventures. “Their ability to translate cutting-edge genomics into tangible clinical impact aligns with our mission to invest in transformative technologies in women’s and sexual health.”
Juniper has completed preclinical validation and is now launching its platform with fertility clinics across the U.S. and Canada. The company is headquartered in Ontario, Canada, with operations and staff across North America.
“Amboy Street Ventures brings a deep understanding of where innovation and impact intersect in fertility,” said Jeremy Grushcow, PhD, JD, Founder and CEO of Juniper Genomics. “We are so grateful that they have come on board during this critical phase of our business, and we’re proud to be a part of their exceptional portfolio. Their support reinforces our belief that improving outcomes in IVF requires not just scientific advancement, but ethical, empathetic care.”
Juniper Genomics is one of ASV’s growing portfolio of brands pioneering women’s health and sexual health solutions alongside Hey Jane, leading tele-health abortion provider; Contraline, the maker of male birth control; and Alloy Women’s Health, a leading menopause tele-health platform. See the full portfolio here. To learn more about Juniper Genomics visit https://www.junipergenomics.com/.
